AbbVie
AbbVie and MD Anderson in cancer research partnership
January 25, 2016Research and Development, Sales and Marketing AbbVie, MD Anderson Cancer Centre, immuno-oncology
AbbVie has announced a new partnership with The University of Texas MD Anderson Cancer Centre, using its immunotherapy platform to …
AbbVie/Roche’s venetoclax bags FDA Breakthrough Therapy Designation
January 21, 2016Sales and Marketing AbbVie, Breakthrough Therapy Designation, FDA, Roche, venetoclax
AbbVie and Roche’s cancer drug venetoclax has been granted Breakthrough Therapy Designation by the FDA in combination with rituximab for …
AbbVie replaces retiring VP of Western Europe and Canada
January 15, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Esteban Plata, Pascale Richetta
AbbVie has appointed Esteban Plata as vice president of Western Europe and Canada.He replaces Pascale Richetta who is retiring from …
AbbVie tests new hepatitis C drug in Phase III trials
January 11, 2016Research and Development AbbVie, clinical trials, hepatitis C, phase III
AbbVie has announced it has begun six global Phase III trials of its once-daily, ribavirin-free investigational hepatitis C virus regimen, …
AbbVie begins late stage trials of rheumatoid arthritis drug
January 11, 2016Manufacturing and Production, Research and Development, Sales and Marketing ABT-494, AbbVie, F-star, JAK-1 inhibitor, rheumatoid arthritis
AbbVie has begun a large phase III clinical trial programme for its next-generation rheumatoid arthritis (RA) treatment ABT-494, which the …
Gilead steps in to rescue Galapagos RA drug
December 18, 2015Sales and Marketing AbbVie, Gilead, Gilead Sciences, filgotinib, inflammation, inflammatory diseases, rheumatoid arthritis
Gilead Sciences is to pay $725million for the rights to filgotinib, a JAK1-selective inhibitor for rheumatoid arthritis and other inflammatory …
New regulatory submissions for AbbVie and Novo Nordisk
December 4, 2015Medical Communications AbbVie, EMA, FDA, Novo Nordisk, Viekira Pak, insulin aspart
AbbVie and Novo Nordisk have submitted new drug applications to the US FDA and European Medicines Agency (EMA) respectively. The …
FDA approves BMS and AbbVie’s Empliciti for multiple myeloma
December 1, 2015Manufacturing and Production, Sales and Marketing AbbVie, BMS, Bristol-Myers Squibb, Empliciti, FDA, elotuzumab, multiple myeloma
The US healthcare regulator has approved Empliciti – a multiple myeloma treatment co-developed by Bristol-Myers Squibb and AbbVie. The FDA …
AbbVie reports 26% rise in Q3 revenues
October 30, 2015Sales and Marketing AbbVie, Humira
AbbVie has announced stronger-than-anticipated Q3 financial results, its revenues increasing 26.2% on the same period last year to $5.944 billion, …
FDA warns AbbVie hep C drugs linked to serious liver damage
October 23, 2015Medical Communications AbbVie
AbbVie stocks tumbled 14% yesterday after the FDA warned that two of the company’s hepatitis C drugs could cause serious …
NICE to recommend three new treatments for hep C
October 16, 2015Medical Communications AbbVie, BMS, Bristol-Myers Squibb, Exviera, Gilead, NICE, Viekirax, daklinza, harvoni, hepatitis C
NICE has recommended Bristol-Myers Squibb’s Daklinza, Gilead’s Harvoni and AbbVie’s Viekirax, with or without Exviera, as treatments for some adults …
Home Secretary Theresa May opens Abbvie’s new UK offices
October 2, 2015Medical Communications AbbVie
AbbVie today opened new UK offices, in a ceremony presided over by Theresa May, Home Secretary and MP for Maidenhead.The company, …
Abbvie and Roche report success in Phase II leukaemia trial
August 13, 2015Research and Development AbbVie, Breakthrough Therapy Designation, CLL, EMA, FDA, Roche, chronic lymphocytic leukaemia, leukaemia, venetoclax
AbbVie plans to submit regulatory applications for its leukaemia drug venetoclax to the FDA and the EMA before the end …
Novavax rides high on crest of RSV vaccine wave
August 12, 2015Research and Development AbbVie, MedImmune, Novavax, RSV, vaccines
The vaccine development company Novavax has announced positive top-line data from a mid-stage clinical trial of its candidate vaccine against …
AbbVie’s Humira receives first European OK for skin condition
August 3, 2015Sales and Marketing AbbVie, Hidradenitis suppurativa, Humira, adalimumab
The European Commission has approved AbbVie’s Humira as a treatment for moderate-to-severe hidradenitis suppurativa – a chronic condition affecting the …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
